摘要
目的探讨华法林在高龄非瓣膜性心房纤颤患者抗凝治疗的疗效及安全性。方法将56例高龄(≥80岁)心房纤颤患者随机分入华法林组和阿斯匹林组各28例,调整华法林用量[使国际标准化比值(INR)达到1.6～2.5],阿斯匹林100 mg/d,观察比较两组患者血栓栓塞与出血事件发生率。结果华法林组发生血栓事件1例(3.6%),阿斯匹林组发生血栓事件5例(17.9%),华法林组发生血栓事件明显低于阿斯匹林组(P=0.007,P<0.05)。华法林组出血事件3例(10.8%),阿斯匹林组2例(7.1%);两组均无因出血病死者(P=0.33,P>0.05)。结论高龄非瓣膜性心房纤颤患者应用华法林抗凝治疗是有效的,但需要更严密观察及监测。
Objeative To investigate antithrombotic effect and safety of adjusted-dose warfarin preventing thrombo-embolism for nonvalvular atrail fibrillation of old age patients. Methods Fifty six cases diagnosed nonvalvular atrail fibrillation in the hospital were divided into two groups randomly：warfarin group（INR1.6-2.5） and aspirin control group（100mg/d）. The effect of warfarin was observed and the incidence of the side-effects such as thrombo-embolism and hemorrhagic was compared. Results The cases of thrombo-embolism in warfarin group were 1 （3.6%）,in aspirin group were 5 （17.9%）.The incidence of thrombo-embolism in aspirin was higher than in warfarin group （P〈0.05）. The bleeding were 3 cases （10.7% ）in warfarin group and 2 cases in aspirin group （P〉 0.05）. There was no died case in two groups. Conclusion Adjusted-dose warfarin is effective to old age patients with nonvalvular atrail fibrillation, perhaps needs more careness during therepy.
出处
《实用医药杂志》
2012年第6期481-482,共2页
Practical Journal of Medicine & Pharmacy
关键词
高龄患者
心房纤颤
华法林
Old age patients
Atrail fibrillation
Warfarin
